118 related articles for article (PubMed ID: 8276298)
1. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival.
Eisenkop SM; Nalick RH; Wang HJ; Teng NN
Gynecol Oncol; 1993 Nov; 51(2):224-9. PubMed ID: 8276298
[TBL] [Abstract][Full Text] [Related]
2. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
3. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
[TBL] [Abstract][Full Text] [Related]
4. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
Bristow RE; Montz FJ
Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
[TBL] [Abstract][Full Text] [Related]
5. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?
Eisenkop SM; Spirtos NM
Gynecol Oncol; 2001 Sep; 82(3):435-41. PubMed ID: 11520137
[TBL] [Abstract][Full Text] [Related]
6. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
8. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
11. Abdominal carcinomatosis in women with a history of breast cancer.
Garg R; Zahurak ML; Trimble EL; Armstrong DK; Bristow RE
Gynecol Oncol; 2005 Oct; 99(1):65-70. PubMed ID: 15979132
[TBL] [Abstract][Full Text] [Related]
12. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
[TBL] [Abstract][Full Text] [Related]
14. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
[TBL] [Abstract][Full Text] [Related]
15. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
16. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
Chi DS; Eisenhauer EL; Zivanovic O; Sonoda Y; Abu-Rustum NR; Levine DA; Guile MW; Bristow RE; Aghajanian C; Barakat RR
Gynecol Oncol; 2009 Jul; 114(1):26-31. PubMed ID: 19395008
[TBL] [Abstract][Full Text] [Related]
17. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
19. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer.
Paulsen T; Kaern J; Kjaerheim K; Haldorsen T; Tropé C
Gynecol Oncol; 2006 Sep; 102(3):447-52. PubMed ID: 16516277
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer.
Eisenkop SM; Spirtos NM
Gynecol Oncol; 2001 Jul; 82(1):143-9. PubMed ID: 11426976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
